Literature DB >> 22236832

Fibroblast activation protein: A potential therapeutic target in cancer.

Rui Liu1, Hui Li, Liang Liu, Jinpu Yu, Xiubao Ren.   

Abstract

The concept of targeting antigens selectively expressed on the surface of tumor capillary endothelial cells or in tumor stroma has emerged as a promising strategy for cancer therapeutics. Identification of stromal targets for anticancer therapy and development of selective inhibitors of these targets are of great clinical interest. Fibroblast activation protein (FAP), a member of the serine protease family, selectively expressed in the stromal fibroblasts associated with epithelial cancers, whereas with low or undetectable expression in the resting fibroblasts of normal adult tissues. The proteolytic activity of FAP has been shown to support tumor growth and proliferation, making it a potential target for novel anticancer therapies, such as those by immune-based approaches.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22236832     DOI: 10.4161/cbt.13.3.18696

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  53 in total

Review 1.  Targeting the tumour stroma to improve cancer therapy.

Authors:  Kenneth C Valkenburg; Amber E de Groot; Kenneth J Pienta
Journal:  Nat Rev Clin Oncol       Date:  2018-06       Impact factor: 66.675

Review 2.  Hematopoietic stem cell-derived adipocytes and fibroblasts in the tumor microenvironment.

Authors:  Ying Xiong; Lindsay T McDonald; Dayvia L Russell; Ryan R Kelly; Katie R Wilson; Meenal Mehrotra; Adam C Soloff; Amanda C LaRue
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

3.  c-Ski activates cancer-associated fibroblasts to regulate breast cancer cell invasion.

Authors:  Liyang Wang; Yixuan Hou; Yan Sun; Liuyang Zhao; Xi Tang; Ping Hu; Jiajia Yang; Zongyue Zeng; Guanglun Yang; Xiaojiang Cui; Manran Liu
Journal:  Mol Oncol       Date:  2013-08-27       Impact factor: 6.603

Review 4.  Targeting angiogenesis and the tumor microenvironment.

Authors:  Jennifer Samples; Monte Willis; Nancy Klauber-Demore
Journal:  Surg Oncol Clin N Am       Date:  2013-07-26       Impact factor: 3.495

5.  APT2 Inhibition Restores Scribble Localization and S-Palmitoylation in Snail-Transformed Cells.

Authors:  Jeannie L Hernandez; Dahvid Davda; Melanie Cheung See Kit; Jaimeen D Majmudar; Sang Joon Won; Margery Gang; Sirisha C Pasupuleti; Alexandria I Choi; Callie M Bartkowiak; Brent R Martin
Journal:  Cell Chem Biol       Date:  2017-01-05       Impact factor: 8.116

6.  Use of single chain antibody derivatives for targeted drug delivery.

Authors:  Yaghoub Safdari; Vahideh Ahmadzadeh; Masoumeh Khalili; Hossein Zarei Jaliani; Vahid Zarei; Vahid Erfani-Moghadam
Journal:  Mol Med       Date:  2016-04-22       Impact factor: 6.354

Review 7.  Identification of Commonly Dysregulated Genes in Non-small-cell Lung Cancer by Integrated Analysis of Microarray Data and qRT-PCR Validation.

Authors:  Zi-Qiang Tian; Zhen-Hua Li; Shi-Wang Wen; Yue-Feng Zhang; Yong Li; Jing-Ge Cheng; Gui-Ying Wang
Journal:  Lung       Date:  2015-04-08       Impact factor: 2.584

8.  Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Authors:  Liang-Chuan S Wang; Albert Lo; John Scholler; Jing Sun; Rajrupa S Majumdar; Veena Kapoor; Michael Antzis; Cody E Cotner; Laura A Johnson; Amy C Durham; Charalambos C Solomides; Carl H June; Ellen Puré; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2013-11-12       Impact factor: 11.151

9.  Fibroblast activation protein in osteosarcoma cells promotes angiogenesis via AKT and ERK signaling pathways.

Authors:  Chao Zeng; Ming Wen; Xiaomei Liu
Journal:  Oncol Lett       Date:  2018-02-12       Impact factor: 2.967

Review 10.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.